RUNX3 derived hsa_circ_0005752 accelerates the osteogenic differentiation of adipose-derived stem cells via the miR-496/MDM2-p53 pathway

Autor: Yifan Huan, Ming Wang, Jing Li, Guohua Lv, Xiyang Li

Publikováno v: Regenerative Therapy
Regenerative Therapy, Vol 18, Iss, Pp 430-440 (2021)

Background Circular RNAs (circRNAs) are non-coding RNAs that play a pivotal role in bone diseases. RUNX3 was an essential transcriptional regulator during osteogenesis. However, it is unknown whether RUNX3 regulates hsa_circ_0005752 during osteogenic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0747b3ae95e6dcf1917df04284706e77
http://europepmc.org/articles/PMC8546365

STING-mediated degradation of IFI16 negatively regulates apoptosis by inhibiting p53 phosphorylation at serine 392

Autor: Yanghua Qin, Feng Ma, Fan Zhang, Jingfei Zhu, Lifen Xie, Sudan He, Dapei Li, Zigang Qiao, Liang Li, Fangrong Shen, Shengchuan Chen, Sanyue Mai, Haiping Yao

Publikováno v: The Journal of Biological Chemistry

Interferon-γ-inducible factor 16 (IFI16) triggers stimulator of interferon (IFN) genes (STING)-dependent type I IFN production during host antiviral immunity and facilitates p53-dependent apoptosis during suppressing tumorigenesis. We have previousl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4a9b5105bfc9cd2960efbb8c871a94
https://doi.org/10.1016/j.jbc.2021.100930

RBR E3 ubiquitin ligases: new structures, new insights, new questions

Autor: Helen Walden, Donald E. Spratt, Gary S. Shaw

Publikováno v: Biochemical Journal

The RBR (RING-BetweenRING-RING) or TRIAD [two RING fingers and a DRIL (double RING finger linked)] E3 ubiquitin ligases comprise a group of 12 complex multidomain enzymes. This unique family of E3 ligases includes parkin, whose dysfunction is linked

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cedff32799050efc0f1ef4664dad485
https://pubmed.ncbi.nlm.nih.gov/24576094

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR α and eradicates acute promyelocytic leukemia cells.

Autor: Shao X; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Chen Y; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Wang W; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Du W; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Zhang X; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Cai M; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Bing S; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China., Cao J; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.; Cancer Center, Zhejiang University, Hangzhou 310058, China.; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China., Xu X; Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China., Yang B; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China., He Q; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.; Cancer Center, Zhejiang University, Hangzhou 310058, China.; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China., Ying M; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.; Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.; Cancer Center, Zhejiang University, Hangzhou 310058, China.

Publikováno v: Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2022 Apr; Vol. 12 (4), pp. 1856-1870. Date of Electronic Publication: 2021 Oct 23.